Artificial pancreas: current progress and future outlook in the treatment of type 1 diabetes.
File(s)
Author(s)
Ramli, Rozana
Reddy, Monika
Oliver, Nick
Type
Journal Article
Abstract
Type 1 diabetes is characterised by insulin deficiency caused by autoimmune destruction of the pancreatic beta cells. The treatment of type 1 diabetes is exogenous insulin in the form of multiple daily injections or continuous subcutaneous insulin infusion. Advances in diabetes technology have been exponential in the past few decades, culminating in studies to develop an automated artificial pancreas, also known as the closed-loop system. This has recently led to a commercially available, hybrid artificial pancreas in the USA and Europe. This review article aims to provide an overview of the rationale for an artificial pancreas system and an update of the current state of artificial pancreas development. We explore the different types of artificial pancreas systems being studied, including the use of adjunctive therapy, and the use of these systems in different groups of users. In addition, we discuss the potential psychosocial impact and the challenges and limitations of implementing artificial pancreas use into clinical practice.
Date Issued
2019-07-01
Date Acceptance
2019-06-01
Citation
Drugs, 2019, 79 (10), pp.1089-1101
ISSN
1179-1950
Publisher
Springer
Start Page
1089
End Page
1101
Journal / Book Title
Drugs
Volume
79
Issue
10
Copyright Statement
© Springer Nature Switzerland AG 2019
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/31190305
PII: 10.1007/s40265-019-01149-2
Subjects
1115 Pharmacology and Pharmaceutical Sciences
Pharmacology & Pharmacy
Publication Status
Published
Coverage Spatial
New Zealand
Date Publish Online
2019-06-12